Tools · Private company · Auburn, WA, US
Syntrix Biosystems, Inc.
Track this companyFree. Adds Syntrix Biosystems, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials128 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- EnzalutamidePhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- LD-Aminopterin oral capsulePhase 2 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Omnitram Oral TabletPhase 2 · Diabetic NeuropathiesClinicalTrials.gov · fetched Nov 12, 2026
- SX-682Phase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- AminopterinPhase 1 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- DecitabinePhase 1 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- DesmetramadolPhase 1 · PainClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Melanoma Stage IIIClinicalTrials.gov · fetched Nov 12, 2026
- SX-682Phase 1 · Melanoma Stage IIIClinicalTrials.gov · fetched Nov 12, 2026
- SX-682Phase 1 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerPHASE2 · RECRUITING · started Oct 6, 2026ClinicalTrials.gov NCT07322341 · fetched Nov 12, 2026
- Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerPHASE2 · RECRUITING · started Nov 18, 2024ClinicalTrials.gov NCT06228053 · fetched Nov 12, 2026
- A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas CancerPHASE2 · RECRUITING · started Nov 8, 2023ClinicalTrials.gov NCT05604560 · fetched Nov 12, 2026
- SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung CancerPHASE2 · RECRUITING · started Apr 6, 2023ClinicalTrials.gov NCT05570825 · fetched Nov 12, 2026
- A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human SubjectsPHASE1 · COMPLETED · started Jan 8, 2021ClinicalTrials.gov NCT04683926 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 23, 2020ClinicalTrials.gov NCT04477343 · fetched Nov 12, 2026
- SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 14, 2020ClinicalTrials.gov NCT04599140 · fetched Nov 12, 2026
- Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic SyndromePHASE1 · RECRUITING · started Jun 30, 2020ClinicalTrials.gov NCT04245397 · fetched Nov 12, 2026
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 12, 2019ClinicalTrials.gov NCT03161431 · fetched Nov 12, 2026
- Omnitram Safety and Efficacy in the Treatment of Diabetic NeuropathyPHASE2 · COMPLETED · started Nov 15, 2018ClinicalTrials.gov NCT03664921 · fetched Nov 12, 2026
- Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe PsoriasisPHASE2 · COMPLETED · started Nov 1, 2018ClinicalTrials.gov NCT03431974 · fetched Nov 12, 2026
- Aminopterin Pharmacokinetic Study In Moderate to Severe PsoriasisPHASE1 · COMPLETED · started Jun 1, 2009ClinicalTrials.gov NCT00937027 · fetched Nov 12, 2026
NIH awards7
- A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma PatientsFiscal year 2026 · $406.5KNIH RePORTER 1R44CA306688-01A1 · fetched Nov 12, 2026
- A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)Fiscal year 2026 · $575.8KNIH RePORTER 5R44CA278187-04 · fetched Nov 12, 2026
- A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS PatientsFiscal year 2026 · $740.3KNIH RePORTER 5R44CA291622-03 · fetched Nov 12, 2026
- A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS PatientsFiscal year 2025 · $627.3KNIH RePORTER 4R44CA291622-02 · fetched Nov 12, 2026
- A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)Fiscal year 2025 · $903.9KNIH RePORTER 5R44CA278187-03 · fetched Nov 12, 2026
- A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS PatientsFiscal year 2024 · $400KNIH RePORTER 1R44CA291622-01A1 · fetched Nov 12, 2026
- A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)Fiscal year 2024 · $745.1KNIH RePORTER 5R44CA278187-02 · fetched Nov 12, 2026